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We  have  previously presented data  to  show that  the parenteral 
administration of natural vitamin C during the incubation period of 
poliomyelitis in  experimentally infected  monkeys is  followed by  a 
distinct change in the severity of the disease (1).  This was indicated 
by the fact that among a  total of 62  C-treated animals 19 survived 
without paralysis and 43 succumbed to the disease, while of a total of 
38 untreated control animals only 2 failed to develop paralysis and 
36 succumbed to the disease.  It appeared therefore that about 30 
per  cent  of  all  monkeys which had  received injections of  ascorbic 
acid escaped paralysis as  contrasted with approximately 5 per cent 
of non-paralytic survivors among the controls, a  margin sufficiently 
large  to  admit  of  little  possibility that  the  observed difference in 
severity of the disease could have beenaccidental.  However, in view 
of the fact that the virus failed to produce paralysis in 100 per cent 
of the  controls, suggesting that  variations in natural resistance do 
occur among normal monkeys, it was considered advisable to repeat 
these experiments once more with a larger number of animals.  There 
was also the need for further investigation of some essential details 
which had hitherto been studied only imperfectly.  Most important 
of these was the question as to the effectiveness of C  treatment at 
various  intervals  following infection  and  the  establishment  of  an 
optimum dosage of ascorbic acid.  It remained also to be determined 
whether or  not synthetic vitamin C  possessed resistance-enhancing 
properties similar to that of the natural preparation. 
* Aided  by  grants  from  The  Rockefeller  Foundation  and  the  President's 
Birthday Ball Commission for Infantile Paralysis Research. 
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Methods 
The present communication deals with observations based on a  total of 282 
intracerebrally infected monkeys, treated at various intervals with various doses 
of vitamin C.  Of these, 181 had received natural vitamin C and 101  either one 
of two different synthetic compounds.  A  total of  98  control monkeys,  which 
were infected intracerebrally with corresponding amounts of virus and remained 
untreated, accompanied these tests.  There is also included a group of 30 animals, 
infected by intranasal instillation of virus and treated with natural vitamin C, and 
15 similarly infected controls.  The virus used for the intracerebral tests was the 
Aycock strain which had been employed in our previous work.  For the nasal 
infection the Rockefeller mixed virus was used.  I 
The general technique followed closely that outlined in detail in a  previous 
paper (1).  Rhesus monkeys weighing from 2000 to 3000 gin. were injected intra- 
cerebrally with amounts of virus (Aycock strain) ranging from 0.01 to 0.1 cc. (1 cc. 
of a  1 : 100 to 1 : 10 dilution) of a  10 per cent suspension.  The intranasal infection 
was accomplished by instilling 1 cc. of a 5 per cent suspension of virus (R. M. V.) 
into each nostril and repeating this procedure 4 hours later.  The treated animals 
received daily subcutaneous injections of vitamin C, the dosage varying from 5 to 
100 rag., for a period of 2 weeks.  Three different preparations of crystalline vita- 
min C were used in these tests.  The first was a product extracted from natural 
sources (Merck), the second and third were synthetic preparations manufactured 
by  either  Merck  and  Company  or  Hoffmann-La  Roche.  Although  all three 
preparations gave the identical reduction values for/-ascorbic acid with the indo- 
phenol reagent, they looked slightly different as far as the texture and color of the 
individual batches were concerned.  The natural product, moreover, was said to 
contain approximately 2.5 per cent of unidentified impurities absent in either of 
the synthetic preparations? 
A total of twelve different series were run, ten of which represented intracerebral 
and two intranasal tests.  The number of treated animals in each series varied 
from 10 to 49, the number of accompanying controls from 5 to 20.  In some of 
these series different C products were used side by side in order to secure more 
strictly comparable data.  The time at which vitamin C  was first administered 
covered a range extending from the 1st to the 5th day of the infection, i.e., until 
shortly before the onset of paralytic symptoms.  All animals were carefully ob- 
served and a  daily temperature record maintained for a  period of from 3  to 4 
weeks.  In case of paralysis or death, an autopsy was made and  the diagnosis 
confirmed by histological examination of the cord.  Some of the surviving animals 
1 This virus was kindly given to us by Dr. Albert B. Sabin d  The  Rockefeller 
Institute. 
We are indebted to Merck and Company for their cooperation in placing at 
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TABLE  I 
Vitamin  C  Tkerapy  in  Experimental  Poliomyelitis 
~ries i  Date  i  Vitamin C 
1936  co. 
1  Oct. 17  0.02  Natural (Merck) 
lg  Iic  i[i 
~t  ¢c  ~c 
2  Nov. 17  0.01  Natural (Merck) 
44  ~C  C4 
4C  C~  CC 
C4  ~  cc 
C4 
3  Dec. 7  0.1  Synthetic (Merck) 
ii  ll  ~¢ 
cl  ~l  cc 
c~ 
1937 
4  Jan. 16  0.05  Synthetic(Merck) 
gc  lc  lc 
lc  cl  c~ 
~c 
5  Feb. 4  "  Natural (Merck) 
~  !  ~  Results 
~,,  "~  ~'~  ~  "~ 
• 
day of 
infec-  rag. 
tion 
1st  5  6  2  1  3 
1st  25  3  1  0  2 
2nd  5  6  3  0  3 
2nd  25  3  2  0  1 
3rd  5  6  0  2  4 
3rd  25  3  0  0  3 
9  5  1  3 
1st  5  5  4  0  1 
1st  25  3  3  0  0 
2nd  5  6  3  1  2 
2nd  25  3  1  0  2 
3rd  5  6  2  0  4 
3rd  25  3  1  0  2 
8  7  0  1 
1st  5  5  3  2  0 
3rd  5  6  3  2  1 
4th  5  5  4  1  0 
5th  5  6  4  2  O 
12  12  0  0 
1st  5  10  10  0  0 
3rd  5  10  8  1  1 
5th  5  10  8  1  1 
5th  50  10  8  1  1 
20  20  0  0 
1st  5  5  4  1  0 
1st  25  5  3  2  0 
3rd  5  5  3  0  2 
3rd  25  4  1  1  2 
5th  5  5  3  2  0 
5th  25  5  3  1  1 
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TABLE  IIConc~d 
Series  Date 
1937 
Feb. 4 
Feb. 25 
Mar. 22 
Mar. 23 
9  Apr. 26 
~  ~  Results 
~ay of 
co.  in  fee-  rag. 
tion 
0.05  Natural (Merck)  5th  50  5  1  2  2 
' ....  '  5th  100  5  3  0  2 
"  Synthetic (Hoffmann-La Roche)  1st  5  5  2  1  2 
"  "  "  1st  25  5  5  0  0 
"  --  --  --  11  11  0  0 
"  Natural (Merck)  5th  25  5  4  0  1 
......  5th  50  5  3  1  1 
"  Synthetic (Hoffmann-La Roche)  3rd  5  5  3  0  2 
"  "  "  3rd  25  5  4  0  1 
"  --  8  8  0  0 
"  Synthetic (Hoffmann-La Roche)  5th  5  5  3  2  0 
......  5th  25  5  4  0  1 
"  "  "  5th  50  5  4  0  1 
......  5th  100  4  3  1  0 
"  --  5  5  0  0 
0.02  Natural(Merck)  3rd  5  10  6  1  3 
"  "  "  3rd  25  10  8  0  2 
tt 
--  10  9  1  0 
0.05  Natural(Merck)  1st  5  15  12  0  3 
"  "  "  1st  25  9  6  0  3 
"  "  "  2rid  25  10  6  1  3 
"  "  "  3rd  25  6  5  0  l 
"  "  "  5th  5  4  3  0  1 
......  5th  100  5  4  0  ! 
"  --  --  --  10  9  0  1 
10  May 24  "  Natural (Merck)  2nd  25  10  ?  0  3 
.....  5  5  0  0 
were  sacrificed,  beginning  with  the  24th  day,  and  their  tissues  examined  for 
vitamin C  content, others were kept until the termination of  1  to  t½ months,  s 
3 The results of the vitamin C titrations will be found in another paper (2). CLAUS  W.  JUNGEBLUT  463 
The protocols of the individual series are given in Table I.  A summary in which 
all intracerebrally infected animals are grouped together according to the kind 
and amount of vitamin C used will be found in Table II, while Table III lists the 
results obtained with treatment begun on different days of the infection.  Table 
IV brings together the results obtained in the two intranasal series. 
RESULTS 
A  study of Table I  shows that in every one of the ten series, ir- 
respective of the size of the infecting dose of virus, a definite though 
variable  number  of  C-treated  animals  escaped  paralysis.  4  Similar 
survivals among accompanying untreated controls occurred only in 
three series, two of the latter rcpresenting animals which had been 
infected with  the smallest amount of virus,  i.e.,  0.02  and 0.01  cc., 
respectively.  While there can therefore be no doubt that thc absence 
of paralysis  among  C-treated animals was  clearly significant in  at 
least seven series in which all corresponding controls succumbed to the 
disease,  the percentage of non-paralytic survivors  in  the  three  re- 
maining series was  considerably higher among .the  treated  animals 
than among the controls.  Thus, in serics 1 we have surviving with- 
out paralysis 16 (59.2  per cent) of 27 treated animals against 3  (33.3 
per cent) of 9  controls, in series 2,  11  (42.3  per cent) of 26 treated 
animals against 1 (12.5 per cent) of 8 controls, and in series 9, 12 (24.4 
per cent) of 49 trcated animals against 1 (10 per cent) of 10 controls. 
Obviously,  the  lighter  infection  favored  the  occurrence  of  non- 
paralytic survivors among both treated and untreated animals alike, 
but to a  dissimilar extent. 
Important differences in the efficacy of the natural and synthetic 
vitamin C preparations are revealed by Table II.  Among a  total of 
181  infccted monkeys, which had becn trcatcd with natural vitamin 
C,  58  (32  per  cent)  survived  without  paralysis,  16  (8.8  per cent) 
developed an atypical attack of poliomyelitis (incubation period longer 
than  2  weeks), and  107  (59.1  pcr  cent)  succumbed to  the  disease 
in  typical fashion.  On  the other hand,  among  a  total  of  101  in- 
4 It should be pointed out that a majority of the non-paralytic survivors pass 
through a distinct fever cycle during the infection, resembling an abortive attack 
of poliomyelitis, and that there are very few animals in which no rise in tempera- 
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fected monkeys which had  been treated with  synthetic vitamin C 
(Hoffmann-La Roche or Merck), 11  (10.8 per cent) survived without 
paralysis,  14 (13.8 per cent) showed an atypical attack of poliomye- 
litis, and 76 (75.2 per cent) succumbed to the disease in a typical man- 
ner.  The above figures should be compared with the results obtained 
with control animals infected with the same amounts of virus which 
remained untreated.  Of a total of 98 controls 5 (5.1 per cent) failed 
to show any paralysis, 2 (2 per cent) developed poliomyelitis after a 
TABLE  II 
Comparison of the Effect  of Natural and  Synthetic Vitamin C in Experimental 
Poliorayditis 
Prelparati°n  °fvltamin  C  ~  Z~ 
~atural  10G  10 
(Merck)  5C  i0 
25  82 
5  79 
181 
~ynthetic  10C  4 
(Merck  or  5C  15 
Hoffmann-  25  15 
La Roche)  5  67 
101 
Controls (un-  --  98 
treated) 
Result 
Typical paralysis 
(incubation  I to 14 
days) 
•  7  (70  per cent) 
4(4o  ....  ) 
51  (62.1  ....  ) 
45  (56.9  ....  ) 
Atypical paralysis  (incubation  over 14 
days) 
0  (0  per cent) 
3  (30  ....  ) 
5(6  ....  ) 
8  (10.1  ....  ) 
No paralysis 
3  (30  per cent) 
3  (30  ....  ) 
26  (31.7  ....  ) 
26  (32.9  ....  ) 
107  (59.1 per cent)  16  (8.8 per cent)  58  (32 per cent) 
3  (75  per cent)  1  (25  per cent)  0  (0  per cent) 
12  (80  ....  )  1  (6.6  ....  )  2  (13.3  ....  ) 
13  (86.6  ....  )  0  (0  ....  )  2  (13.3  ....  ) 
48  (71.6  ....  )  12  (17.6  ....  )  7  (10.4  ....  ) 
76  (75.2 per cent)  14  (13.8 per cent)  11  (10.8 per cent) 
91  (92.8 per cent)  2  (2 per cent)  5  (5.1 per cent) 
prolonged incubation period, and 91  (92.8  per  cent)  succumbed to 
typical paralysis. 
It  is  therefore evident that  the percentage of non-paralytic sur- 
vivors following treatment  with  natural  vitamin  C  was  about  six 
times as  large  as  that  of  the  untreated  controls.  In  the  animals 
treated  with  synthetic vitamin  C  this  percentage was  only  twice 
that of the controls.  In both treated groups the percentage of ani- 
mals  developing  atypical  paralysis  was  approximately  the  same, CLAUS  W.  JUNGEBLUT  465 
between 5 and 6 times as large as that observed among controls.  How- 
ever the difference  between the two treated  groups is again  clearly 
demonstrated  by  the  fact  that  treatment  with  natural  vitamin  C 
had  reduced the incidence of typical paralysis by about one-third  as 
compared with the controls (from 92.8 to 59.1 per cent), while the re- 
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no. 
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Day  of paralysis.  P.P.-Partial paralysis 
C~A~T 1.  Delayed paralysis in C-treated monkeys. 
duction  for  the  two  synthetic  preparations  combined was less than 
one-fifth  (from 92.8  to  75.2  per  cent). 
Detailed data  concerning the delayed onset of paralysis in a  total 
of 30 C-treated monkeys are given in Chart  1.  It will be noted that 
the incubation period in these animals extended from a  minimum  of 466  VITAMIN C THERAPY IN  POLIOMYELITIS 
15 days to a  maximum of 47 days.  Although these animals carried 
live virus in the central nervous system for long periods of time, there 
was no immunizing effect from such a carrier state as indicated by the 
fact that a majority developed eventually severe prostrating paralysis. 
The figures given in Table II, even though listed according to dos- 
age of vitamin C, do not lend themselves readily to a fair evaluation 
of the relative efficacy of different amounts of vitamin C since treat- 
ment  with  such  doses  was  begun  on  various  days  of  the  disease. 
Caution  should therefore be used in  their interpretation.  As  they 
stand, however, there is very little difference in the percentage of non- 
paralytic survivors among the several groups treated with different 
amounts of natural vitamin C, the figures running from 30 per cent 
to 32.9 per cent.  A  similar uniformity may be observed in the re- 
sults  obtained  following  treatment  with  synthetic  vitamin  C,  ex- 
cept that the figures for all doses are consistently lower, ranging from 
0 per cent in a  small group of 4 animals treated with 100 mg. to be- 
tween 10.4 per cent and  13.3  per cent for the remaining groups. 
A detailed analysis of our data according to the kind of vitamin C 
used,  dosage  employed and  day of first  administration  is  given  in 
Table III.  It becomes at once apparent that the number of animals 
in some of the subdivisions, particularly with the synthetic prepara- 
tions,  is  too  small  to  allow  of  a  fair  interpretation.  However  it 
would seem that the administration of 5 or 25 mg. of natural vitamin 
C,  begun on the day of infection, produces about  the same result, 
i.e.,  between 22.5  per cent and 25 per cent of the animals surviving 
without  paralysis.  When  the first  administration  of vitamin  C  is 
delayed until the 2nd and 3rd day of the infection, considerably higher 
percentages of non-paralytic survivors are observed, especially among 
the animals injected with 5 mg.  Thus it would appear that between 
41.6 per cent and 48 per cent of the animals treated with 5 mg. and 
between 34.6 per cent and 38.4 per cent of those treated with 25 mg. 
of vitamin C  escape paralysis at that time.  We are rather inclined 
to  the  belief that  the  seemingly better  figures  are  more  apparent 
than  real  and  do  not indicate  a  real improvement of  C  treatment 
at the later stages of the disease.  It should be remembered that a 
great portion of the animals listed in these two categories were taken 
from series  1  and  2  in which very small doses of virus were used, CLAUS  W.  JUNGEBLUT  467 
resulting in an abnormally high accumulation of non-paralytic sur- 
vivors among both  treated animals and  controls.  If an  allowance 
were made for this fact and the figures brought into accord with those 
of  the  other  categories,  the  percentage of  non-paralytic  survivors 
among animals treated at this time would not materially exceed 30 
per cent to 35 per cent.  However there would still remain a  slight 
advantage in  favor of the  animals treated with  5  rag.  over those 
treated  with  25  rag.  More  conclusive  results  are  obtained  with 
animals in which vitamin C  treatment was not begun until the 5th 
day of the disease.  At this time distinctly larger doses of vitamin C 
are apparently required to obtain significant results.  Thus the per- 
centage of non-paralytic survivors increases progressively from 11.1 
per cent (5 rag.) to 20 per cent (25 mg.), and reaches a maximum of 
30 per cent when doses of 50 to 100 rag. are used. 
Much less regular results are observed in animals treated with the 
two synthetic preparations, due, in part at least, to the small number 
of  animals  in  some  of  the  subdivisions.  However,  here  again  it 
would seem that better figures are obtained with animals treated on 
the 3rd day of the disease  (about 20 per cent) than with those in 
which treatment was begun on the day of infection (0 to 5 per cent). 
While the percentage of non-paralytic survivors shows also a tendency 
to drop when treatment is delayed until the 5th day of the disease, 
there is no unmistakable correlation to the size of the dose employed. 
In comparing the results obtained with natural and with synthetic 
vitamin C  it can safely be stated that,  irrespective of the interval 
that  had  elapsed  since  infection,  the  percentage  of  non-paralytic 
survivors among animals treated with  natural vitamin C,  dose for 
dose, is distinctly higher than that observed for animals which had 
received either of the two synthetic preparations.  Good results can 
still be obtained with natural vitamin C until the 3rd day, and fair 
results, with adequate dosage, on the 5th day of the disease.  Treat- 
ment with synthetic vitamin C, on the other hand, is so irregular, on 
the whole, and so inefficient that it is doubtful whether the data will 
bear critical examination, except for the suggestion of a slight reduc- 
tion in the severity of the disease as compared with untreated con- 
trols. 
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C was studied on the course of experimental  poliomyelitis induced by 
nasal  instillation  of  the  virus.  In  all  animals  treatment  was  begun 
TABLE  III 
Effect  of  Various  Doses  of Natural  and  Synthetic  Vitamin  C  When  Administered 
on Different Days of Infection 
Pr, tioo  4  o~,~t.~, c  ~.~  ~  ~.! 
r~g. 
Natural  1st  5  31 
(Merck)  25  20 
2m  5  12 
25  26 
3rd  5  27 
25  26 
5th  5  9 
25  10 
50  10 
ilO0  10 
181 
Reset 
ppical paralysis 
ncubafion I to 14 
days) 
22  2 
13  2 
6  1 
16  1 
11  3 
15  1 
6  2 
7  1 
4  3 
7  0 
Atypical paralysis 
(incubation  over 14 
days) 
107  (59.1 per cent)  16  (8.8 per cent) 
5ynthetic  1st  5  20  15 
(Merck  25  5  5 
or Hoff- 
mann-La  3rd  5  21  14 
Roche)  25  5  4 
4th  5  26  19 
and  25  5  4 
5th  50  15  12 
100  4  3 
No  paralysis 
7  (22.5 per cent) 
5  (25  ....  ) 
5  (41.6  ....  ) 
9  (34.6  ....  ) 
13  (48  ....  ) 
10  (38.4  "  "  ) 
1  (11.1  ....  ) 
2  (2o  ....  ) 
3  (30  ....  ) 
3  (3o  ....  ) 
101  76  (75.2 per cent) 
Controls  98  91 (92.8 per cent) 
untreated) 
14  (13.8 per cent) 
2  (2 per cent) 
58  (32 per cent) 
2  (5  per cent) 
o(o  ....  ) 
4  (19  ....  ) 
1 (20  ....  ) 
1  (3.8  ....  ) 
i  (20  ....  ) 
2  (13.3  ....  ) 
0  (0  ....  ) 
11  (10.8 per cent) 
5  (5.1 per cent) 
on the  day  of  infection  and maintained,  as  usual,  for  a  period  of  2 
weeks.  The results are given in Table IV.  It will be noted that all CLAUS  W.  JUNGEBLUT  469 
10 animals injected with 5 rag.  of vitamin  C  succumbed  to  the  dis- 
ease, as did 9 of 10 animals injected with 25 rag.  On the other hand, 
there  were  9  animals  that  escaped  paralysis  among  a  group  of  10 
monkeys which had  received doses of 50 to  100  nag.  of vitamin  C. 
Since all of the  15 untreated controls which accompanied these tests 
developed  paralysis,  it  would  seem  that  very  encouraging  results 
may be obtained with vitamin  C treatment in this type of infection, 
although  much  larger  doses of ascorbic acid  are  evidently required 
than for intracerebral  tests.  However it is planned to continue this 
work on a  larger  scale before valid conclusions can be drawn. 
TABLE  IV 
E.~ext of Natural Vitamin C in Experimental Poliomyelitis 
(Intranasal Infection) 
Series 
11 
12 
Dose of vitamin 
C 
mg. 
5 
25 
5O 
100 
Number of 
animals  Typical 
.paralysis 
(incubation 
1 to 14 days) 
10 
8 
10 
10 
10 
10 
1 
0 
5* 
Result 
Atypical. 
. para.ly~. 
~incubation 
over 14 days) 
No paralysis 
* One of the 5 controls listed in series 12 as developing typical paralysis showed 
no distinct paralysis of the extremities but a very marked facial paralysis. 
It  seems to  us that  the  significance  of results obtained in  thera- 
peutic  studies,  such  as  the  one  here  reported,  lies  not  so much  in 
isolated observations of success, or lack of success, obtained in one or 
several  small  experimental  series,  but  that  their  intrinsic  value  is 
considerably strengthened  if such  results  can  be duplicated  in  pro- 
longed investigations.  For this reason it is interesting to compare the 
data obtained in this study with those published in our previous re- 
port, even though the  two  studies  differ substantially among them- 
selves in important  details such as dosage of vitamin  C, time of ad- 470  VITAMIN  C  THERAPY  IN  POLIOMYELITIS 
ministration, and amount of virus used.  It will be noted from Table 
V that the two sets of figures are in exceptionally good agreement. 
Thus  the  average  percentage  of  intracerebrally infected monkeys 
which escape paralysis following  treatment with natural vitamin C 
stands  between 30.6 per  cent  and  32  per cent, while only between 
5.1 per cent and 5.2 per cent of the untreated controls fail to develop 
paralytic symptoms.  These data are now based on  a  total of 243 
(181 plus 62) treated monkeys and 136 (38 plus 98)  controls, leaving 
little  doubt  as  to  the  accuracy  of  the  observations.  However, 
further detailed statistical analysis of the two sets of figures  shows 
TABLE  V 
Effect of Natural  Vitamin  C in Experimental  Poliomyelitis 
(Comparison  of Data Obtained in This Study with Data Previously Published) 
Expefi  -  mental  Type of 
data  animal 
Present 
data...  C-treated 
Previous 
data...  "  " 
Present 
data...  Controls 
Previous 
data...  " 
Result 
Typical paralysis  Atypical paralysis  No paralysis 
181  107  (59.1 per cent) 
62  38(61.1  ....  ) 
98  91  (92.8  ....  ) 
38  34  (89.4  ....  ) 
16  (8.8 per cent) 
5(8  ....  ) 
2(2  ....  ) 
2  (5.2  ....  ) 
58  (32  per cent) 
19  (30.6  ....  ) 
s  (5.t  ....  ) 
2  (5.2  ....  ) 
that the percentage of animals treated with 5 mg. alone has not in- 
considerably  dropped  from  that  reported  heretofore.  Accidental 
features, connected with the limited number of animals used, may 
have caused the first figure to be unduly high.  There is also a possi- 
bility  that  different preparations  of  natural vitamin  C  may differ 
conspicuously in the degree of their purity or the extent to which 
other extraneous substances may modify the therapeutic effect. 
DISCUSSION 
The data presented in this paper, which are based on a number of 
experimental animals almost thrice as large as previously reported, CLAUS  W.  JUNGEBLUT  471 
leave no doubt that the administration of natural vitamin C during 
the incubation period of experimental poliomyelitis is followed by a 
definite alteration in the severity of the disease.  This is indicated 
by  the  fact  that  about  six times  as  many  treated  animals escape 
paralysis  (32  per cent)  as do corresponding controls (5.1  per cent). 
Conversely, the incidence of typical paralysis stands at 59.1 per cent 
among the treated monkeys as compared with 92.8 per cent among 
untreated  control  animals.  The  given  percentages  are  essentially 
identical with those previously published by us, i.e.,  there has been 
neither a  significant reduction nor a  conspicuous increase, when the 
data  are  taken  as  a  whole.  These figures demonstrate clearly the 
possibilities as well as the limitations of therapy with natural vita- 
min C  in experimental poliomyelitis. 
Different results were obtained when synthetic vitamin C was used. 
In contrast to the above figures, we find only about twice as many 
non-paralytic survivors in animals treated with this substance (10.8 
per cent) as among the controls, and the incidence of typical paralysis 
stands at 75.2 per cent in this treated group. 
It would appear, therefore, that the measure of therapeutic suc- 
cess depends upon certain variables which, in order of significance, 
may be listed as follows: FirSt, the kind of vitamin C; second, the 
dosage of vitamin C; third, the rapidity of the infection as determined 
by the amount of virus and type of strain; and fourth, the time of 
first administration of vitamin C.  As a  fifth factor, equally as im- 
portant as the other four, we should mention differences in individual 
response from monkey to  monkey which necessitate  running large 
series of animals if significant results are to be obtained. 
The markedly superior therapeutic efficacy of natural vitamin C, 
as  contrasted with  the  synthetic preparations,  is  surprising,  since 
we found but little discrepancy in virucidal action between the two 
in in vitro  experiments.  It is realized that the assumption of a  real 
difference between the two kinds of products will find little favor with 
the biochemist who considers them as identical, except for possible 
impurities in  ascorbic  acid  extracted  from  natural  sources.  Simi- 
larly,  clinical experience has proven that both preparations possess 
the  same  antiscorbutic properties in  man  and  animals.  However, 
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contains additional factors, absent in the chemically pure synthetic 
product, which may be present in variable amounts in natural prepa- 
rations.  We are alluding here to the so called P factor discovered by 
Szent-Gy6rgyi  (3)  which exerts  an  antipurpuric  effect  and  the  so 
called J  factor  of von  Euler  and  Malmberg  (4)  which apparently 
protects against pneumococcic infection in  guinea pigs.  Divergent 
results  between  synthetic  and  natural  vitamin  C  have  also  been 
described by Havas and Gal (5) who found that the same concentra- 
tion of ascorbic  acid  either  stimulated or inhibited the  growth of 
seedlings, depending upon whether the natural or synthetic product 
were employed.  There is finally a possibility that mineral impurities 
of the natural product may serve as activators (6). 
The problem of dosage is complicated by the fact that the largest 
amounts of ascorbic acid are not always necessarily optimal.  This is 
dearly shown by  a  series of recent observations in widely differing 
fields all of which demonstrate that excessive amounts of vitamin C 
may bring about a  reversal of the effect noticed with smaller doses 
(7).  While our data are still too limited to make deductions certain, 
it would appear that during the first few days of the infection doses 
of 5 to 25 mg. produce an optimum therapeutic effect and that defi- 
nitely larger  doses,  ranging  from  50  to  100  mg.,  are  required for 
treatment which is delayed until shortly before the expected onset of 
paralytic symptoms.  For  the same reason it  can easily be  under- 
stood that a faster progressing infection such as that induced by the 
R.M.V.  strain responds only to doses of vitamin C  definitely larger 
than those which are sufficient to halt the slower infection with the 
Aycock virus.  The different dosage required for  the two  types of 
infections can certainly more easily be explained on that basis than 
by assuming differences in type of strain or mode of infection.  The 
size of the effective dose of vitamin C therefore seems to be directly 
proportional to the speed of the infection and the stage at which the 
infectious process is advanced. 
It is altogether impossible to say why the therapeutic effect should 
be so irregular, varying as it does, series for series,  among different 
animals even  though the  average  percentage of non-paralytic  sur- 
vivors remains fairly well fixed.  The nature of this individual factor 
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which determine the extent to which vitamin C proves of benefit to 
the monkey.  From the results of our vitamin C titrations of various 
monkey tissues it  would seem possible  that the  protected animals 
may utilize vitamin C more effectively than the unprotected ones (2). 
Whether  the  degree of this utilization  depends upon an  unknown 
endocrine factor is an open question. 
The mechanism by which vitamin C  accomplishes its therapeutic 
effect  still  remains  obscure.  Obviously  the  simplest  explanation 
would be to assume that ascorbic acid, not unlike a chemotherapeutic 
agent, inactivates poliomyelitis virus directly in the central nervous 
system, particularly since the latter can be shown to store this sub- 
stance.  Such inactivation would then be largely non-specific, since 
ascorbic acid,  properly adjusted for pH,  has proven capable  of in- 
activating by direct contact in  vitro  every toxin and virus that has 
been investigated (8).  However in spite of the frequent occurrence 
of such crude "antiviral" and "antitoxic" phenomena in vitro,  thera- 
peutic results with vitamin C have been obtained only in a minority 
of infectious diseases, among which tuberculosis (9)  and diphtheria 
(10)  are outstanding.  This would suggest that vitamin C may con- 
ceivably act in a  more specialized manner in certain types of tissue 
injury by enhancing the mechanism of natural defense.  An example 
of such action is found in the observation that mice injected with 
vitamin C are protected against fatal doses of acetonitril (11), a poison 
to which they are seasonally more susceptible in the summer than in 
the  winter  (12).  Evidence  supporting the  supposition that  polio- 
myelitis virus is not destroyed directly by the vitamin in vivo  comes 
from our observation that a  considerable number of treated animals 
develop paralysis  after  greatly  prolonged  incubation  periods,  i.e., 
at  a  time following discontinuance of C  treatment when the artifi- 
dally raised C levels have dropped again to their normal values (see 
Chart 1).  In such cases the virus was dearly not killed but kept in 
check possibly as long as the cells  maintained a  high concentration 
of vitamin C.  The irregularity of the therapeutic effect,  so  char- 
acteristic of all our experiments, would also plead in favor of a com- 
plex reaction,  mediated through the  cells,  rather than for a  direct 
virucidal action. 
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that the chemist has superseded the pharmacologist who must surely 
recognize the probability that substances of an intensive physiological 
activity may exercise therapeutic functions that may seem compara- 
tively  remote  from  their  normal  nutritional  mode  of  action  (13). 
And  such  phrases  as  "conditioned  vitamin  deficiencies"  or  "toxic 
avitaminoses" continue  to appear in the literature  devoted  to  this 
new and promising field.  If we are to accept vitamin C,  therefore, 
as  a  therapeutic agent on the basis  of its  established physiological 
action rather than of its normal r61e in nutrition, the question arises 
in what way the anti-infectious effect of ascorbic acid in poliomyelitis 
can be correlated with its biochemical activity.  Since it is commonly 
suspected that one of the functions of vitamin C  is to regulate the 
oxidation-reduction potential of cellular respiration  (14),  it becomes 
relatively easy to imagine that  an increased supply of the vitamin, 
which has a tendency to diminish during the infection, serves to main- 
tain the oxidation-reduction system of nerve cells at a level at which 
the  oxylabile  virus  is  restrained  from  intracellular  propagation. 
While this suggestion is still entirely hypothetical, it is in harmony 
with the observations of Brodie and Wortis  (15)  who have demon- 
strated a  diminution in the oxygen consumption rate of nerve tissue 
infected with poliomyelitis virus. 
In  the light  of these remarks it  will readily be  understood why 
vitamin  C  may be useful as  an  auxiliary therapeutic agent in  cer- 
tain infectious diseases which have little in common with the classical 
symptoms of frank scurvy.  As far as poliomyelitis is concerned, the 
rationale  of  such  treatment,  at  present,  is  predicated only by the 
experimental data  given  in  this  paper.  It  would be  considerably 
strengthened by the establishment of a  causal relationship between 
susceptibility to the disease and faulty C metabolism.  Such demon- 
stration would have to come from clinical studies and from epidemi- 
ological observations involving a correlation between the extent of the 
so  called prescorbutic  state  in  different age  groups,  latitudes,  and 
seasons,  on  the  one  hand,  and  the  distribution  of  cases  of  polio- 
myelitis, on the other.  It is not likely, however, that abnormally low 
C levels are summarily produced by a low intake of vitamin C, except 
in regions where the content of vitamin C  in food is notoriously in- 
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It would seem rather as if the C  requirements of exceptional indi- 
viduals at certain times are greater than can be met and that crises 
occur, precipitated by a  combination of environmental factors such 
as light, fatigue, intestinal disturbances, and other unknown agencies, 
which may facilitate central nervous system invasion of the ubiquitous 
virus. 
SUMMARY  AND  CONCLUSIONS 
1.  A  group  of  181  monkeys were  infected intracerebrally with 
amounts of virus ranging from 0.01 to 0.05 cc. of a  10 per cent virus 
suspension.  At  different intervals following  infection treatment of 
these animals was begun with  daily injections of  5  to  100  rag.  of 
natural vitamin C for a period of 2 weeks.  Of 89 monkeys treated 
on the ist or 2nd day of infection 26 (29.2 per cent) survived without 
showing any evidence of paralysis; of 53 monkeys treated on the 3rd 
day of the infection 23 (43.3 per cent) survived without showing any 
evidence of paralysis; of 39 monkeys treated on the 5th day of the 
infection 9  (23 per cent) survived without showing  any evidence of 
paralysis. 
2.  A  group  of  101  monkeys were  infected intracerebrally with 
amounts of virus ranging from 0.05 to 0.1  cc. of a  10 per cent virus 
suspension.  At  different intervals following  infection treatment of 
these animals was begun with  daily injections of 5  to  100  rag.  of 
synthetic vitamin C for a period of 2 weeks.  Of 25 monkeys treated 
on the 1st day of infection 2 (8 per cent) survived without showing 
any evidence of paralysis; of 26 monkeys treated on the 3rd day of 
the infection 5 (19.2 per cent) survived without showing any evidence 
of paralysis; of 50 monkeys  treated on the 4th and 5th day of the infec- 
tion 4 (8 per cent) survived without showing any evidence of paralysis. 
3.  The above two groups of treated animals were accompanied by 
a  group of 98  control monkeys which were infected intracerebrally 
with the same amounts of virus and remained untreated.  In this 
group there were 5  (5.1 per cent)  animals which survived without 
showing any evidence of paralysis. 
4.  The figures,  taken as a  whole,  show that among 181  monkeys 
treated with natural vitamin C 58  (32  per  cent)  survived without 
paralysis, and among 101 monkeys treated with synthetic vitamin C 476  VITAMIN  C THERAPY IN  POLIOMYELITIS 
11  (10.8  per  cent)  survived without paralysis.  In  comparing the 
percentage  of  non-paralytic  survivors  of  the  two  treated  groups 
with that of the untreated controls (5.1  per cent)  it is found that 
about six times as many animals escaped paralysis following treat- 
ment with natural vitamin C as did the corresponding controls.  In 
the group of animals treated with synthetic vitamin C, on the other 
hand, there were only about twice as many non-paralytic survivors 
as among the controls. 
5.  The results obtained in this investigation, as far as they are con- 
cerned with the  therapeutic effect of natural vitamin  C  in  experi- 
mental poliomyelitis, are in close agreement with the data previously 
published. 
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